文献速递血脂与心血管预防冠心病

中国ASCVD高危与极高危患者降脂治疗现状分析

[Analysis of lipid-lowering therapy in Chinese patients at high and very high risk of atherosclerotic cardiovascular disease].
PubMed 文献 · Zhonghua Xin Xue Guan Bing Za Zhi · 2026-01-01

结果显示LDL-C达标率低(高危16.7%、极高危18.0%),高强度治疗率低(5.0%和17.0%),高龄、农村、女性及非冠脉ASCVD患者治疗强度更低。

要点

  • 高危和极高危患者LDL-C达标率仅16.7%和18.0%,未治疗率分别为36.9%和14.4%。
  • 高强度降脂治疗率低:高危5.0%,极高危17.0%,以中等强度他汀单药为主。
  • 年龄>75岁、农村居住、女性、卒中或外周动脉疾病与较低治疗强度相关。

核心结论

  • 中国ASCVD高危与极高危患者降脂治疗存在明显治疗惰性与不均,LDL-C达标率低,指南推荐的高强度方案应用严重不足。

主要发现

  • 多因素分析:年龄>75岁(高危OR=0.55,95%CI:0.49~0.61;极高危OR=0.51,95%CI:0.46~0.57)和农村居住(高危OR=0.69,95%CI:0.66~0.73;极高危OR=0.64,95%CI:0.60~0.68)与较低治疗强度相关。

关键数值与推荐

  • 极高危女性接受任何降脂治疗OR=0.62(95%CI:0.57~0.67),高强度治疗OR=0.90(95%CI:0.84~0.97)。
  • 卒中患者高强度治疗OR=0.41(95%CI:0.38~0.44),外周动脉疾病OR=0.28(95%CI:0.22~0.36),均相对于心肌梗死和冠心病患者。

临床怎么用

  • 应关注高龄、农村、女性及非冠脉ASCVD患者,纠正治疗惰性,提高高强度降脂方案的使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the utilization, intensity, and associated factors of lipid-lowering therapy in Chinese patients at high or very high risk of atherosclerotic cardiovascular disease (ASCVD). Methods: This nationwide hospital-based cross-sectional study was led by Peking University First Hospital. Patients at high or very high risk of atherosclerotic cardiovascular disease (ASCVD) were recruited from 1 785 medical institutions across China between September 2022 and November 2024. Clinical data, including age, gender, and lipid profiles, were collected. We described the utilization status of lipid-lowering therapy and identified factors associated with the intensity of lipid-lowering therapy using multivariate logistic regression analysis. Results: A total of 189 674 ASCVD patients were included in the final analysis (153 066 high-risk (80.7%); 36 608 very high-risk (19.3%)). Low density lipoprotein cholesterol attainment rates were low in both high-risk (25 542/153 066, 16.7%) and very high-risk (6 585/36 608, 18.0%) groups. Non-treatment rates were 36.9% (56 436/153 066) in high-risk and 14.4% (5 280/36 608) in very high-risk patients. Treatment in both groups was predominantly moderate-intensity statin monotherapy, while high-intensity treatment rates were low (5.0% high-risk (7 685/153 066); 17.0% very high-risk (6 240/36 608)). Multivariate analysis showed that age >75 (high-risk patients: OR=0.55, 95%CI: 0.49-0.61; very high-risk patients: OR=0.51, 95%CI: 0.46-0.57) and rural residence (high-risk patients: OR=0.69, 95%CI: 0.66-0.73; very high-risk patients: OR=0.64, 95%CI: 0.60-0.68) were significantly associated with lower treatment intensity. Women in the very high-risk group had a lower propensity to receive any lipid-lowering treatment (OR=0.62, 95%CI: 0.57-0.67) and high-intensity therapy (OR=0.90, 95%CI: 0.84-0.97). Patients with stroke (OR=0.41, 95%CI: 0.38-0.44) or peripheral arterial disease (OR=0.28, 95%CI: 0.22-0.36) received less high-intensity therapy compared to those with myocardial infarction and coronary heart disease. Conclusion: Significant clinical inertia and disparities in lipid-lowering therapy exist among Chinese patients at high-risk or very high-risk of ASCVD, characterized by low LDL-C attainment rates and insufficient use of guideline-recommended intensive regimens, especially among the elderly, rural residents, women, and patients with non-coronary ASCVD. 目的: 分析中国动脉粥样硬化性心血管疾病(ASCVD)高危与极高危患者降脂药物治疗的使用现状、强度及相关因素。 方法: 本研究为多中心横断面研究,由北京大学第一医院牵头,选取2022年9月至2024年11月在全国1 785家医疗卫生机构就诊的ASCVD高危或极高危患者。收集其年龄、性别、血脂指标等临床信息,描述其降脂治疗应用情况,并通过多因素logistic回归分析降脂治疗强度的相关因素。 结果: 共纳入189 674例ASCVD患者,其中高危153 066例(80.7%),极高危36 608例(19.3%)。高危与极高危患者低密度脂蛋白胆固醇达标率均低,分别为16.7%(25 542/153 066)和18.0%(6 585/36 608)。高危患者未治疗率为36.9%(56 436/153 066),极高危患者为14.4%(5 280/36 608)。两组患者的降脂治疗皆以中等强度他汀单药为主,高等强度治疗率低[高危患者5.0%(7 685/153 066),极高危患者17.0%(6 240/36 608)]。多因素logistic回归分析显示,在高危和极高危患者中,年龄>75岁(高危患者OR=0.55,95%CI:0.49~0.61;极高危患者OR=0.51,95%CI:0.46~0.57)、农村居住(高危患者OR=0.69,95%CI:0.66~0.73;极高危患者OR=0.64,95%CI:0.60~0.68)等因素与高等强度降脂治疗强度负相关。在极高危患者中,女性与接受降脂治疗(OR=0.62,95%CI:0.57~0.67)及高等强度治疗(OR=0.90,95%CI:0.84~0.97)负相关;与心肌梗死和冠心病的ASCVD患者相比,卒中(OR=0.41,95%CI:0.38~0.44)、外周动脉疾病(OR=0.28,95%CI:0.22~0.36)与高等强度治疗负相关。 结论: 当前中国ASCVD高危与极高危患者降脂治疗存在明显的治疗惰性与治疗不均,低密度脂蛋白胆固醇达标率低,指南推荐的高等强度治疗方案应用严重不足,尤其在老年、农村、女性及非心肌梗死和冠心病ASCVD患者中问题更加突出。.

来源:Zhonghua Xin Xue Guan Bing Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang L, Zhou ZY, Zhou SD, et al. [Analysis of lipid-lowering therapy in Chinese patients at high and very high risk of atherosclerotic cardiovascular disease]. Zhonghua Xin Xue Guan Bing Za Zhi. 2026. PMID: 41866205. doi:10.3760/cma.j.cn112148-20251116-00805

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。